Overview

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the dose proportionality of 5 mg, 20 mg and 40 mg of PF 00345439 formulation under fed conditions in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pain Therapeutics
Treatments:
Oxycodone